How to buy CytomX Therapeutics stock (CTMX)

CytomX Therapeutics is a biotechnology business based in the US. CytomX Therapeutics shares (CTMX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.09 – a decrease of 1.8% over the previous week. CytomX Therapeutics employs 120 staff and has a trailing 12-month revenue of around $126.6 million.

Our top picks for where to buy CytomX Therapeutics stock

Buy CytomX Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

CytomX Therapeutics stock price (NASDAQ: CTMX)

Use our graph to track the performance of CTMX stocks over time.

CytomX Therapeutics shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$1.09
52-week range	$0.83 - $5.85
50-day moving average more info button	$1.07
200-day moving average more info button	$1.53
Wall St. target price	$5.29
PE ratio more info button	6.625
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$0.16

Is it a good time to buy CytomX Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

CytomX Therapeutics price performance over time

Historical closes compared with the close of $1.1 from 2024-12-19

1 week (2024-12-13)	-0.90%
1 month (2024-11-21)	26.95%
3 months (2024-09-20)	-7.56%
6 months (2024-06-21)	-14.73%

1 year (2023-12-21)	-21.99%
2 years (2022-12-21)	-27.15%
3 years (2021-12-21)	3.87
5 years (2019-12-20)	8.79

Is CytomX Therapeutics stock undervalued or overvalued?

Valuing CytomX Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of CytomX Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

CytomX Therapeutics's P/E ratio

CytomX Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 7x. In other words, CytomX Therapeutics shares trade at around 7x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

CytomX Therapeutics's EBITDA

CytomX Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $8.6 million.

The EBITDA is a measure of a CytomX Therapeutics's overall financial performance and is widely used to measure a its profitability.

CytomX Therapeutics financials

Revenue TTM	$126.6 million
Operating margin TTM	12.3%
Gross profit TTM	$53.2 million
Return on assets TTM	2.33%
Return on equity TTM	-5475.03%
Profit margin	10.92%
Book value	$-0.30
Market Capitalization more info button	$83 million

TTM: trailing 12 months

CytomX Therapeutics share dividends

We're not expecting CytomX Therapeutics to pay a dividend over the next 12 months.

CytomX Therapeutics share price volatility

Over the last 12 months, CytomX Therapeutics's shares have ranged in value from as little as $0.833 up to $5.85. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while CytomX Therapeutics's is 1.061. This would suggest that CytomX Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

CytomX Therapeutics overview

CytomX Therapeutics, Inc. , an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc.

Frequently asked questions

null
What percentage of CytomX Therapeutics is owned by insiders or institutions?
Currently 1.002% of CytomX Therapeutics shares are held by insiders and 65.668% by institutions. How many people work for CytomX Therapeutics?
Latest data suggests 120 work at CytomX Therapeutics. When does the fiscal year end for CytomX Therapeutics?
CytomX Therapeutics's fiscal year ends in December. Where is CytomX Therapeutics based?
CytomX Therapeutics's address is: 151 Oyster Point Boulevard, South San Francisco, CA, United States, 94080 What is CytomX Therapeutics's ISIN number?
CytomX Therapeutics's international securities identification number is: US23284F1057 What is CytomX Therapeutics's CUSIP number?
CytomX Therapeutics's Committee on Uniform Securities Identification Procedures number is: 23284F105